ImmunityBio, Inc. , a leading immunotherapy company, will announce new clinical findings for ANKTIVA® (nogapendekin alfa inbakicept-pmln) in non-muscle invasive bladder cancer carcinoma in situ (NMIBC ...

The stock market fell sharply anew on Wednesday, with all major indices ending in the red, as investor sentiment was dampened ...

In terms of financial performance, ImmunityBio reported that its Q1 2025 Anktiva unit sales volume grew by 150% over the unit ...

ImmunityBio, Inc.’s IBRX share price has dipped by 6.65%, which has investors questioning if this is right time to buy.

ImmunityBio, Inc. ( NASDAQ: IBRX ), a leading immunotherapy company, today announced that it has completed multiple submissions to the FDA including an sBLA for BCG-unresponsive NMIBC in papillary ...

We recently published a list of Biotech Stocks Dominate Monday’s Top 10 Gainers. In this article, we are going to take a look ...

Highlights,Institutional allocation shifts observed, with Corebridge Financial Inc. lowering its exposure to ImmunityBio in the fourth quarter.,ImmunityBio opened at a relatively lower price compared ...

US biotech ImmunityBio (Nasdaq: IBRX) has secured $75 million through a direct offering with a single institutional investor, ...

In this article, we are going to take a look at where ImmunityBio Inc. (NASDAQ:IBRX) stands against other Tuesday’s worst-performing stocks. Wall Street’s main indices suffered a bloodbath on ...

We recently published a list of Tuesday’s 10 Worst-Performing Stocks. In this article, we are going to take a look at where ImmunityBio Inc. (NASDAQ:IBRX) stands against other Tuesday’s ...

CULVER CITY, Calif.--(BUSINESS WIRE)-- ImmunityBio, Inc. (IBRX) (NASDAQ: IBRX), a leading immunotherapy company, today announced that it has executed financing to provide further working capital ...